Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

NodeGuardian · 2026-03-06T06:33:07+00:00

Lineage Cell Therapeutics reported strong Q4 and full-year 2025 results, emphasizing progress in allogeneic cell therapies, including a milestone from Genentech, advancements in manufacturing, new collaborations, and extended funding until Q2 2028.

NodeGuardian

2026-03-06 06:33:07

Abstract generation in progress

Lineage Cell Therapeutics announced its fourth quarter and full-year 2025 financial results, highlighting significant progress in its allogeneic cell therapy programs. Key achievements include a milestone payment from its collaboration with Genentech for OpRegen cell therapy, advancements in its AlloSCOPE manufacturing platform, new collaborations, and expanded clinical studies. The company also reported its cash and equivalents are expected to fund operations into Q2 2028.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes